Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 25, pages 1243–1248 (2000)Cite this article

Abstract

The purpose of the study was to determine the toxicities and effectiveness of a novel preparative regimen of busulfan (Bu) 14 mg/kg, etoposide 50 or 60 mg/kg, and cyclophosphamide (Cy) 120 mg/kg in non-Hodgkin's lymphoma (NHL) and to analyze results using doses based on different body weight parameters and the two different etoposide doses. Three hundred and eighty-two patients aged 16 to 72 underwent first autologous transplantation with mobilized peripheral blood progenitor cells between August 1992 and December 1998 at either of two transplant centers. Mucositis was the most common toxicity. Hepatic toxicity was the most common life-threatening toxicity; severe hepatic VOD occurred in 11 patients (2.9%). Ten patients (2.6%) died from treatment-related toxicity. The 3-year progression-free survival (PFS) for the entire group was 46.9% (95% CI, 40.5–53.3%). Elevated LDH, resistance to chemotherapy, and intermediate/aggressive histology were significant adverse prognostic factors. For patients in sensitive first relapse PFS was 47.0% (95% CI, 37–57%). Neither etoposide dose nor body weight parameter utilized significantly affected outcome. In conclusion, the novel preparative regimen of Bu, etoposide and Cy results in a low incidence of treatment-related mortality and is effective in the treatment of patients with NHL. Bone Marrow Transplantation (2000) 25, 1243–1248.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493–1498

    Article  CAS  PubMed  Google Scholar 

  2. Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis New Engl J Med 1987 316: 1499–1505

    Article  CAS  PubMed  Google Scholar 

  3. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation J Clin Oncol 1992 10: 936–941

    Article  CAS  PubMed  Google Scholar 

  4. Vose JM, Armitage JO, Bierman PJ et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing bone marrow transplantation Am J Med 1989 87: 285–288

    Article  CAS  PubMed  Google Scholar 

  5. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  PubMed  Google Scholar 

  6. Schouten H, Colombat P, Verdonck L et al. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: The European Bone Marrow Transplant Group experience Ann Oncol 1994 5: 147–149

    Article  PubMed  Google Scholar 

  7. Horning SJ . Treatment approaches to the low-grade lymphomas Blood 1994 83: 881–884

    CAS  PubMed  Google Scholar 

  8. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma Blood 1995 86: 3257–3262

    CAS  PubMed  Google Scholar 

  9. Haas R, Moos M, Möhle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 1996 17: 149–155

    CAS  PubMed  Google Scholar 

  10. Bierman PJ, Vose JM, Andersen JR et al. High-dose therapy with autologous hematopoietic rescue for follicular non-Hodgkin's lymphoma J Clin Oncol 1997 15: 445–450

    Article  CAS  PubMed  Google Scholar 

  11. Seng JE, Peterson BA . Indolent B-cell non-Hodgkin's lymphoma Oncology 1997 11: 1883–1894

    CAS  PubMed  Google Scholar 

  12. Weaver CH, Schwartzberg L, Rhinehart S et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 1998 21: 383–389

    Article  CAS  PubMed  Google Scholar 

  13. Stiff PJ, Dahlberg S, Forman SJ et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens – A Southwest Oncology Group Trial J Clin Oncol 1998 16: 48–55

    Article  CAS  PubMed  Google Scholar 

  14. Avalos BR, Klein JL, Kapoor PJ et al. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY Bone Marrow Transplant 1993 12: 133–138

    CAS  PubMed  Google Scholar 

  15. Philip T, Chauvin F, Armitage J et al. Parma International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation Blood 1991 77: 1587–1592

    CAS  PubMed  Google Scholar 

  16. Chopra R, Goldstone AH, Pearch R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Tansplant Group Registry Data J Clin Oncol 1992 10: 1690–1695

    Article  CAS  PubMed  Google Scholar 

  17. Vose JM, Bierman PJ, Lynch JC et al. Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma J Clin Oncol 1998 16: 844–849

    Article  CAS  PubMed  Google Scholar 

  18. Rapaport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome J Clin Oncol 1993 11: 2351–2361

    Article  Google Scholar 

  19. Copelan EA, Deeg HJ . Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation Blood 1992 80: 1648–1658

    CAS  PubMed  Google Scholar 

  20. Jones RJ, Piantadosi S, Mann RB et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 1990 8: 527–537

    Article  CAS  PubMed  Google Scholar 

  21. Copelan EA, Kapoor N, Gibbins B et al. Allogeneic marrow transplantation for non-Hodgkin's lymphoma Bone Marrow Transplant 1990 5: 47–50

    CAS  PubMed  Google Scholar 

  22. deMagalhaes-Silverman M, Lister J, Rybka W et al. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma Bone Marrow Transplant 1997 19: 777–781

    Article  CAS  Google Scholar 

  23. Yeager AM, Shinn C, Pardoll DM . Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice Blood 1991 78: 3312–3316

    CAS  PubMed  Google Scholar 

  24. Fishleder AJ, Bolwell B, Lichtin AE . Incidence of mixed chimerism using busulfan/cyclophosphamide containing regimens in allogeneic bone marrow transplantation Bone Marrow Transplant 1992 9: 293–297

    CAS  PubMed  Google Scholar 

  25. Reece DE, Shepherd JD, Klingmann HG et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 117–123

    CAS  PubMed  Google Scholar 

  26. Schiller G, Nimer S, Vescio R et al. Phase I–II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma Bone Marrow Transplant 1994 14: 131–136

    CAS  PubMed  Google Scholar 

  27. Copelan EA, Biggs JC, Avalos BR et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia J Clin Oncol 1992 10: 237–242

    Article  CAS  PubMed  Google Scholar 

  28. Styler MJ, Crilley P, Biggs J et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis Bone Marrow Transplant 1996 18: 171–176

    CAS  PubMed  Google Scholar 

  29. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 11: 255–267

    Article  Google Scholar 

  30. Burt RK, Deeg HJ, Lothian ST, Santos GW (eds) . Bone Marrow Transplantation. RG Landes Co, Chapman & Hall: New York, NY 1996

    Google Scholar 

  31. Bensinger WI, Buckner CD, Clift RA et al. Phase I study of busulfan and cyclophosphamide in preparation for autologous marrow transplant for patients with multiple myeloma J Clin Oncol 1992 10: 1492–1497

    Article  CAS  PubMed  Google Scholar 

  32. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide following by autologous stem-cell support in patients with malignant lymphoma J Clin Oncol 1994 12: 2559–2566

    Article  CAS  PubMed  Google Scholar 

  33. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2552–2558

    Article  CAS  PubMed  Google Scholar 

  34. Copelan EA, Ceselski SK, Ezzone SA et al. Mobilization of peripheral blood progenitor cells with high dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease J Clin Oncol 1997 15: 759–765

    Article  CAS  PubMed  Google Scholar 

  35. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  PubMed  Google Scholar 

  36. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  37. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170

    CAS  PubMed  Google Scholar 

  38. Cox DR . Regression models and life tables J Roy Stat Soc 1972 34: 187–220

    Google Scholar 

  39. Curtis R, Rowlings P, Deeg H et al. Solid cancers after bone marrow transplantation New Engl J Med 1997 336: 897–904

    Article  CAS  PubMed  Google Scholar 

  40. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy Blood 1994 83: 3780–3786

    CAS  PubMed  Google Scholar 

  41. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2535–2542

    Article  CAS  PubMed  Google Scholar 

  42. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies J Clin Oncol 1994 12: 2527–2534

    Article  CAS  PubMed  Google Scholar 

  43. Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 1–6

    Google Scholar 

  44. Andersson BS, Fernandez H, Cagnoni P et al. IV busulfan, cyclophosphamide (BuCy) and hemopoietic stem cells for non-Hodgkin's lymphomas (NHL). Proceedings of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28–March 6, 1999 (No.2, p3; Abstr.)

  45. Vaughan WP, Cagnoni P, Fernandez H et al. Pharmacokinetics of intravenous busulfan in hematopoietic stem cell transplantation (HSCT). Proceedings of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28–March 6, 1999 (No. 78, p22; Abstr.)

  46. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61

    Article  CAS  PubMed  Google Scholar 

  47. Grochow LB . The role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: 18–25

    CAS  PubMed  Google Scholar 

  48. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  49. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  50. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 1996 14: 1484–1494

    Article  CAS  PubMed  Google Scholar 

  51. Cleland BD, Pokorny CS . Cyclophosphamide related hepatotoxicity Aust NZ J Med 1993 23: 408

    Article  CAS  Google Scholar 

  52. Modzelewski JR, Daeschner C, Joshi VV et al. Veno-occlusive disease of the liver induced by low dose cyclophosphamide Mod Pathol 1994 7: 967–972

    PubMed  Google Scholar 

  53. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 1992 10: 995–1000

    Article  CAS  PubMed  Google Scholar 

  54. Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia Blood 1999 93: 2196–2201

    CAS  PubMed  Google Scholar 

  55. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation Bone Marrow Transplant 1989 4: 559–565

    CAS  PubMed  Google Scholar 

  56. Crilley P, Topolsky D, Bulova S et al. Toxicity of a busulfan-VP-16-cyclophosphamide conditioning regimen in patients undergoing marrow transplantation for advanced high-risk hematologic malignancies Blood 1991 78: 245a (Abstr.971)

    Google Scholar 

  57. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to the nursing and house staff of the Cleveland Clinic Foundation and The Arthur G James Cancer Hospital at The Ohio State University for their compassionate and detailed work on our units. We would also like to thank the referring physicians for their trust in our care of their patients, and Norma Haas for preparing the manuscript.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Program, The Ohio State University, Arthur G James Cancer Hospital & Richard J Solove Research Institute, Columbus, Ohio, USA

    EA Copelan, SL Penza, BR Avalos, TP Bechtel, MD Scholl, PJ Elder, SA Ezzone, LC O'Donnell, MB Tighe, GL Risley & DC Young

  2. Bone Marrow Transplantation Program, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    B Pohlman, M Goormastic, SW Andresen, M Kalaycio & BJ Bolwell

Authors
  1. EA Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SL Penza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. BR Avalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Goormastic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. SW Andresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. TP Bechtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. MD Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. PJ Elder
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. SA Ezzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. LC O'Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. MB Tighe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. GL Risley
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. DC Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. BJ Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copelan, E., Penza, S., Pohlman, B. et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25, 1243–1248 (2000). https://doi.org/10.1038/sj.bmt.1702433

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702433

Keywords

This article is cited by

Search

Advanced search

Quick links